Sponsor pipeline

National Heart, Lung, and Blood Institute (NHLBI) clinical trial pipeline

Get alerts when National Heart, Lung, and Blood Institute (NHLBI)'s trials change

Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

4 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 3 with minor changes only.

Notable

Sirolimus (Rapamune ) for Relapse Prevention · Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Primary endpoint(s) modified

Also in this update: Results posted: Oct 6, 2026

National Heart, Lung, and Blood Institute (NHLBI)Phase 2 NCT02979873 Registry history of NCT02979873 on ClinicalTrials.gov (opens the registry)

Oct 6, 2026

Show 3 trials with minor changes only

Minor

Milk Oligosaccharide-Based Synbiotic Supplement for Intestinal Microbiota Dysbiosis

Trial completed

Also in this update: Final enrollment: 46 participants (planned 100); Primary completion date changed from estimate of Apr 15, 2027 to Jul 28, 2026

National Heart, Lung, and Blood Institute (NHLBI)Early Phase 1 NCT06615986 Registry history of NCT06615986 on ClinicalTrials.gov (opens the registry)

Oct 13, 2026
Minor

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

Trial completed

Also in this update: Final enrollment: 94 participants (planned 110); Primary completion date changed from estimate of Jul 31, 2027 to Mar 24, 2026

National Heart, Lung, and Blood Institute (NHLBI)Phase 2 NCT03372733 Registry history of NCT03372733 on ClinicalTrials.gov (opens the registry)

Oct 5, 2026
Minor

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

Start date changed from estimate of Sep 27, 2026 to Sep 18, 2026

National Heart, Lung, and Blood Institute (NHLBI)Phase 3 NCT07613099 Registry history of NCT07613099 on ClinicalTrials.gov (opens the registry)

Sep 23, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Early Phase 1		2
Phase 1		7
Phase 1/2		13
Phase 2		11
Phase 3		1
Phase 4		1

Not charted: 56 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 21

Heart Disease (20) · Sickle Cell Disease (16) · Chronic Lymphocytic Leukemia (CLL) (8) · Leukemia (8) · Hypertension (7) · Thalassemia (7) · Heart Failure (6) · Myelodysplastic Syndromes (MDS) (6) · Diabetes (4) · Obesity (4)

Get alerts when National Heart, Lung, and Blood Institute (NHLBI)'s trials change

Status changes, date slips, and new filings: detected daily, delivered to your inbox.

Start monitoring free